Compare Biogen Inc (BIIB) vs Kohl's Corporation (KSS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Kohl's Corporation — how do they compare? Biogen Inc trades at $191.22 (market cap $28.34B), while Kohl's Corporation trades at $16.46 (market cap $1.86B). The key difference: Biogen Inc is far larger — about 15.2× Kohl's Corporation's market cap, and Kohl's Corporation pays a 3.04% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | KSS | |
|---|---|---|
Market Cap | $28.34B | $1.86B |
Sector | Health | Consumer Cyclical |
52-Week High | $216.63 | $24.71 |
52-Week Low | $122.68 | $9.27 |
Enterprise Value | $30.62B | $7.97B |
Dividend Yield | — | 3.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.
The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.
Kohl's (KSS) trades at $16.55, down 1.49% today, showing mixed signals with bearish technical indicators but attractive valuation metrics including a P/E of 6.95 and P/B of 0.47. Recent earnings have consistently beaten expectations, with Q1 2026 showing early turnaround progress despite revenue declines. The company maintains a 40.52% gross margin and positive cash flow from operations of $648M in 2025, while implementing strategic changes including new leadership appointments and proprietary brand expansion.
KSS presents a value opportunity with deep discount valuations, though facing significant headwinds from declining revenues and competitive pressures. The stock's near-term trajectory depends on successful execution of turnaround initiatives and proprietary brand growth, with analyst consensus at $16.75 offering modest upside potential from current levels amid cautious market sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Kohl's Corporation
Kohl's operates 1,165 department stores in 49 states that sell moderately priced private-label and national brand clothing, shoes, accessories, cosmetics, and home furnishings. Most of these stores are in strip centers. Kohl's also operates a large digital sales business. Women's apparel is Kohl's largest category, having generated 27% of its 2021 sales. The retailer, headquartered in Menomonee Falls, Wisconsin, opened its first department store in 1962.
Read more on KSS →
